Johnson & Johnson announces expected settlement of Actelion tender offer on June 16, 2017

Actelion Pharmaceuticals Ltd / Johnson & Johnson announces expected settlement of Actelion tender offer on June 16, 2017 . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

• Announces receipt of all regulatory approvals required to complete acquisition of Actelion

ALLSCHWIL/BASEL, SWITZERLAND - 09 June 2017 - Johnson & Johnson (NYSE:JNJ) today announced that, with today's receipt of approval of the proposed acquisition of Actelion Ltd (SIX: ATLN) from the European Commission (EC), all regulatory approvals required to complete the transaction have been received. Johnson & Johnson expects the settlement of the all-cash public tender offer by its Swiss subsidiary, Janssen Holding GmbH, to acquire all publicly held shares of Actelion Ltd for $280 per share, payable in U.S. dollars, on June 16, 2017.

As previously announced, as part of the transaction, Actelion will spin out its drug discovery operations and early-stage clinical development assets into a newly created Swiss biopharmaceutical company ("Idorsia Ltd"). The shares of Idorsia Ltd are expected to be distributed to Actelion's shareholders as a dividend in kind and listed on the SIX Swiss Exchange on the day of the settlement of the public tender offer. A Johnson & Johnson subsidiary will initially hold 9.9 percent of the shares of Idorsia Ltd and has rights to potentially increase up to 32 percent through a convertible note.

###

Notes to the editor

About Johnson & Johnson
Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 130,800 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

About the Janssen Pharmaceutical Companies of Johnson & Johnson
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com. Follow us at www.twitter.com/JanssenUS and www.twitter.com/JanssenGlobal.